Engineered immune cells target Hard-to-Treat autoimmune conditions
NCT ID NCT06347718
Summary
This early-stage trial is testing whether modified immune cells called CAR-T cells can help control severe autoimmune diseases like lupus, scleroderma, and muscle inflammation diseases. The treatment involves collecting a patient's own immune cells, genetically modifying them to target harmful B cells, and returning them after chemotherapy. Researchers are primarily checking if this approach is safe while also measuring whether it improves disease symptoms and reduces harmful antibodies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universitätsklinikum Erlangen
RECRUITINGErlangen, Bavaria, 91054, Germany
Contact
Contact
Conditions
Explore the condition pages connected to this study.